Leerink Partnrs Weighs in on Vaxcyte FY2029 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Vaxcyte in a note issued to investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings of $2.42 per share for the year. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the firm posted ($0.91) EPS.

Several other equities research analysts have also issued reports on PCVX. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $145.71.

Vaxcyte Stock Performance

Shares of PCVX opened at $89.29 on Tuesday. The stock has a 50 day simple moving average of $89.10 and a 200 day simple moving average of $93.56. Vaxcyte has a 52-week low of $58.10 and a 52-week high of $121.06. The firm has a market capitalization of $11.13 billion, a PE ratio of -19.41 and a beta of 0.98.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Riverview Trust Co bought a new position in Vaxcyte in the 3rd quarter worth $27,000. Blue Trust Inc. grew its holdings in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after buying an additional 93 shares during the last quarter. Quest Partners LLC purchased a new stake in Vaxcyte during the 2nd quarter valued at $70,000. Meeder Asset Management Inc. increased its holdings in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. bought a new stake in shares of Vaxcyte in the third quarter worth approximately $92,000. Institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total value of $669,280.00. Following the completion of the transaction, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 42,000 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,429,294.37. This trade represents a 31.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 113,732 shares of company stock worth $11,730,787 in the last 90 days. Insiders own 3.10% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.